![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MHRA Supports Avelumab With Axtinib for Advanced Renal Cancer
MHRA Supports Avelumab With Axtinib for Advanced Renal Cancer
November 13, 2019
The MHRA’s Early Access to Medicines Scheme (EAMS) has issued a positive opinion for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) as a first-line treatment for advanced renal cancer.
The two drugs are administered intravenously in an 800-milligram dose over 60 minutes every two weeks, with axitinib 5 mg taken orally twice daily with or without food.
The early access scheme provides earlier availability of promising new unlicensed medicines to UK patients with a high unmet clinical need.
Upcoming Events
-
21Oct